Amgen appoints Michael V. Drake to Board of Directors effective August 3, 2022

AMGEN INC

Dr. Drake is president of the University of California, with medical and academic leadership background.
Board now has 13 directors, 12 of whom are independent.
He will serve on the Corporate Responsibility & Compliance and Governance & Nominating Committees.
Standard director compensation includes pro-rated annual retainer of $105,000, committee retainer of $12,500, and RSU grant valued at $210,000.
No arrangements or transactions exist between Dr. Drake and Amgen.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael V. Drake

director

AMGN · AMGEN INC

Effective: 2022-08-03
Filed: August 3, 2022, 7:59 PM ET

On August 3, 2022, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Michael V. Drake as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael V. Drake was appointed as director at AMGEN INC.

Action: appointed
Role: director

Exact text from the filing

On August 3, 2022, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Michael V. Drake as a director of the Company, effective immediately.

View on SEC.gov

AMGEN INC filing history →

Source: SEC EDGAR

accession 0001193125-22-211269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.